 |
 Video: What is a Stock Split?
|
|
|
| Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic compounds to treat diseases through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Pegcetacoplan targets C3, the central protein of the complement cascade. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. According to our Apellis Pharmaceuticals stock split history records, Apellis Pharmaceuticals has had 0 splits. | |
|
Apellis Pharmaceuticals (APLS) has 0 splits in our Apellis Pharmaceuticals stock split history database.
Looking at the Apellis Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Apellis Pharmaceuticals shares, starting with a $10,000 purchase of APLS, presented on a split-history-adjusted basis factoring in the complete Apellis Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
11/10/2017 |
|
| End date: |
04/25/2024 |
|
| Start price/share: |
$14.00 |
|
| End price/share: |
$47.93 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
242.36% |
|
| Average Annual Total Return: |
21.00% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$34,244.38 |
|
| Years: |
6.46 |
|
|
|
|
|
